Subject: Endocrinology | Article Type: Review Article
Type 2 Diabetes Mellitus: Pathogenesis, Screening, and Emerging Therapies
Editorial Team | Medical Education & Research Portal
In collaboration with: Osh State University Faculty of Medicine, Kyrgyzstan | I.K. Akhunbaev Kyrgyz State Medical Academy
ABSTRACT
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder of global significance. This review examines current understanding of T2DM pathogenesis, including insulin resistance and beta-cell dysfunction, and evaluates evidence-based screening protocols and novel pharmacological strategies, with attention to their applicability in low- and middle-income settings including Kyrgyzstan.
1. Introduction
T2DM affects over 537 million people worldwide (IDF Diabetes Atlas, 2021) and is projected to reach 643 million by 2030. In Kyrgyzstan, the national diabetes registry documents a steadily rising prevalence, particularly in urban populations of Osh and Bishkek. The Osh Regional Hospital Endocrinology Department, in partnership with the Postgraduate Medical Institute of Kyrgyzstan, has led national screening initiatives. Collaborative research with Sri Ramachandra Institute of Higher Education and Research (Chennai, India) has informed regionally adapted clinical protocols.
2. Pathogenesis
T2DM develops through the interplay of insulin resistance—primarily in skeletal muscle, liver, and adipose tissue—and progressive beta-cell failure. Inflammatory cytokines, lipotoxicity, glucotoxicity, and mitochondrial dysfunction all contribute. Recent evidence highlights the role of the gut microbiome in modulating insulin sensitivity, an area of active investigation at both Kyrgyz National University’s Biology Department and the Indian Council of Medical Research (ICMR).
3. Clinical Presentation and Screening
Many patients with T2DM are asymptomatic for years. Screening using fasting plasma glucose (FPG ≥126 mg/dL) or HbA1c (≥6.5%) is recommended for high-risk individuals—those with BMI >25 kg/m², family history, hypertension, or dyslipidemia. Population-based screening programs in Osh Oblast, supported by WHO Kyrgyzstan Country Office, have demonstrated that opportunistic screening in primary care settings can detect undiagnosed T2DM in up to 12% of screened adults.
4. Management
Lifestyle modification (dietary change, physical activity) forms the cornerstone of T2DM management. Pharmacotherapy begins with metformin unless contraindicated. Second-line agents include SGLT-2 inhibitors (empagliflozin, dapagliflozin), GLP-1 receptor agonists (liraglutide, semaglutide), and DPP-4 inhibitors. SGLT-2 inhibitors and GLP-1 RAs offer proven cardiovascular and renal protective benefits and are increasingly recommended for patients with established cardiovascular disease or chronic kidney disease.
5. Emerging Therapies
Novel therapeutic approaches include dual GIP/GLP-1 receptor agonists (tirzepatide), stem cell-based beta-cell regeneration, and closed-loop insulin delivery systems. Bariatric surgery achieves sustained T2DM remission in eligible patients. Pharmacogenomics-guided therapy is an emerging frontier explored in joint research between I.K. Akhunbaev Kyrgyz State Medical Academy and Jawaharlal Nehru Medical College (Wardha, India).
6. Conclusion
T2DM management requires an integrated approach combining lifestyle intervention, evidence-based pharmacotherapy, and regular monitoring for complications. Building regional capacity for diabetes care—through academic partnerships, telemedicine infrastructure, and community health worker programs—is essential for Central Asian healthcare systems.
References
1. International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels: IDF; 2021.
2. American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1).
3. Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in T2DM. N Engl J Med. 2015;373:2117–2128.
4. Kyrgyz Ministry of Health. National Strategy for Prevention of Non-communicable Diseases 2020–2025. Bishkek; 2020.
5. Gupta N, et al. Diabetes care in South Asia: current status and future directions. Lancet Diabetes Endocrinol. 2022;10(5):367–380.
Note: This article is prepared for educational and informational purposes by the editorial team. It is not a substitute for professional medical advice. References are cited for further reading.